PCV13

ApprovedBiologic

Sanofi

PCV13 is one of 171 biologic programs targeting Pneumonia. It is currently in Approved.

Indications

Total Trials

Active Trials

170

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

MemoryActive, not recruiting

Multiple MyelomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

ANCA-Associated VasculitisActive, not recruiting

AsthmaActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

MemoryApproved

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaApproved

Active, not recruiting

ANCA-Associated VasculitisPhase 2

Active, not recruiting

AsthmaApproved

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

PCV13

Sanofi

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunogenicity5 trials

Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT04384107·694 enrolled

Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers

Completed· Sanofi logo

Sanofi·Phase 3·NCT03205371·1,183 enrolled

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants

Completed·LLondon School of Hygiene and Tropical Medicine·Phase 4·NCT03489018·2,100 enrolled

Show 2 more trials

Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children

Completed·UUniversity of Witwatersrand, South Africa··NCT04275284·600 enrolled

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

Completed·AAffinivax, Inc.·Phase 1·NCT04525599·75 enrolled

Memory3 trials

Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients

Unknown status·—·Phase 4·NCT03041051·40 enrolled

B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

Unknown status·—·Phase 4·NCT01846923·37 enrolled

Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels

Completed·JJena University Hospital·Phase 4·NCT02637583·123 enrolled

Vaccine3 trials

13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study

Completed·UUniversity of Oxford·Phase 4·NCT01095471·100 enrolled

Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Completed·MMurdoch Childrens Research Institute·Phase 2/3·NCT01953510·1,400 enrolled

CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study

Completed·UUniversity of British Columbia·Phase 2/3·NCT03384589·248 enrolled

Immunity1 trial

A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years

Completed·BBeijing Minhai Biotechnology Co., Ltd·Phase 4·NCT06210737·621 enrolled

Multiple Myeloma1 trial

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00566098·26 enrolled

9 more indications

Vaccines1 trial

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

Completed·—·Phase 4·NCT03530124·223 enrolled

Bone Marrow Transplant1 trial

Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01282216·120 enrolled

Vaccination1 trial

Fever After Simultaneous Versus Sequential Vaccination in Young Children

Completed·—·Phase 4·NCT03165981·221 enrolled

Pneumonia1 trial

Burden of Hospitalized Pneumonia in Korea COPD Population

Unknown status·—··NCT03046134·384 enrolled

Asthma1 trial

Pneumococcal Vaccines in Patients With Asthma

Completed·MMayo Clinic·Phase 4·NCT03260790·17 enrolled

ANCA-Associated Vasculitis1 trial

Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03069703·96 enrolled

Single Ascending Dose1 trial

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

Completed· GSK logo

GSK·Phase 1/2·NCT03803202·630 enrolled

Pneumococcal Disease1 trial

PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)

Unknown status·LLiverpool School of Tropical Medicine·Phase 4·NCT04974294·516 enrolled

Chronic Lymphocytic Leukemia1 trial

Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia

Completed·RRegion Örebro County·Phase 4·NCT05316831·77 enrolled

Sources

References

[1]
ClinicalTrials.gov — 22 trial records for PCV13. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PCV13 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PCV13. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Sanofi

PCV13

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunogenicity5 trials

Memory3 trials

Vaccine3 trials

Immunity1 trial

Multiple Myeloma1 trial

Vaccines1 trial

Bone Marrow Transplant1 trial

Vaccination1 trial

Pneumonia1 trial

Asthma1 trial

ANCA-Associated Vasculitis1 trial

Single Ascending Dose1 trial

Pneumococcal Disease1 trial

Chronic Lymphocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News